DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

May 28, 2024

What is ZAP-X® to Treat Brain Cancer?

ZAP-X® GYROSCOPIC RADIOSURGERY®

zap trademark

As the first new dedicated radiosurgery technology developed in nearly half a century, ZAP-X® looks to set new standards in surgical robotics, radiosurgical safety and efficacy, as well as patient comfort and convenience.

ZAP-X radio surgery

Radiosurgery, also commonly referred to as SRS (stereotactic radiosurgery), is well recognized as an alternative to surgery for effectively treating many brain tumors, brain metastases, meningiomas, as well as other vascular and functional diseases within the head.

Unique from surgery however, radiosurgery requires no incision or anesthesia, and is painless. SRS is typically delivered in one to five brief outpatient visits and patients often return to normal activity the same day as the procedure.

COMFORT & CONVENIENCE

  • Simple outpatient procedure
  • No scalpels or incisions
  • No pain or discomfort originating from the SRS treatment
  • No invasive and often painful head frames
  • Most patients experience little or no recovery time
  • Patients often return to normal activity the same day as the procedure
  • “Vault-free” design eliminates the historical need for prolonged patient isolation in a concrete radiation bunker during treatment

SAFETY

  • Novel gyroscopic beam mobility strictly controls incidental radiation exposure to critical structures such as the brain stem, eyes, and optic nerves.
  • Ground-breaking design aims to reduce clinically significant healthy brain tissue exposure, thus mitigating the possibility of affecting patient cognitive function.
Zap-X Non invasive radio surgery for brain tumors

Sponsor logos

Hand holding cell phone displaying app

EBCI App QR

Scan or click the QR code to download the App now!

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram